DBV Technologies shares among the biggest gainers on the SBF 120, +4.5%
The Châtillon-based biotech rebounds sharply mid-session, while the SBF 120 rises modestly. This rebound comes a week after quarterly accounts accompanied by a warning on the going concern assumption, and while the file for the peanut allergy patch is still under review by the FDA.
A rebound that brings the stock back above its 20-day moving average without erasing the quarter's decline
The DBV Technologies share gains 4.37% to €1.84, among the biggest gainers on the SBF 120. It extends the move begun on Tuesday, when the stock had already led the Paris market with a jump of nearly 9%. The price thus moves back above its MM20, at €1.72 (a 7% gap), but remains below its MM50 at €1.96.
The respite is real without being decisive: the stock still loses 20.4% over three months and 3.4% over one week, so the rebound of the day mitigates this decline more than it erases it.
The RSI at 51 is neutral. The support at €1.57, approached in early November, remains the key reference low, while the resistance at €2.07 is the nearest ceiling.
On the short side, the disclosures consulted list five funds holding a cumulative 3.30% of the capital, down 0.70 points over one month: the bearish bet remains in place but is loosening.
After the doubt over the going concern, a final regulatory stretch expected in the fourth quarter
The accounts for the first nine months, published on October 28, showed a loss of $64.5 million in the third quarter and serious doubt about the company's ability to continue operating over the next twelve months.
The company states that it needs additional capital to fund its operations beyond the third quarter of 2027. It has, however, raised $50 million through an ADS issuance and renewed an at-the-market issuance program of $150 million.
Meanwhile, the marketing authorization application for the Viaskin Peanut patch in children aged 4 to 7 has been filed, with a priority review requested and an FDA response expected in the fourth quarter of 2026.
A second filing, for children aged 1 to 3, is planned for 2027. These regulatory deadlines, more than the day's market movement, outline the next steps for the file.
